Second Hospital of Shanxi Medical University
山西医科大学第二医院
Listed for 15 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Second Hospital of Shanxi Medical University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Oesophageal squamous cell carcinoma食管鳞状细胞癌1 paper led
- Osteosarcoma骨肉瘤16 papers led
- Multiple myeloma多发性骨髓瘤6 papers led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
- Haemophilia A血友病 A6 papers led
- Fanconi anaemia范可尼贫血1 paper led
- IgG4-related diseaseIgG4相关性疾病4 papers led
- Takayasu arteritis大动脉炎1 paper led
- Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
- Fabry disease法布雷病0 papers led
- Behçet disease白塞病1 paper led
- IgA nephropathyIgA 肾病4 papers led
- Osteogenesis imperfecta成骨不全症0 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
Not listed for: Nasopharyngeal carcinoma, Hepatocellular carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 1 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.03%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Taiyuan for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led1
More papers found outside PubMed (not counted)2
Cancer
Osteosarcoma
骨肉瘤Led 16 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Taiyuan for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led16
- GBP1-CDK9-STAT3 signaling axis promotes osteosarcoma PD-L1 expression and immune escape.
- DDTC-Cu(I) inhibits human osteosarcoma cells growth by repressing MET/PI3K/AKT signaling pathway.
- Genetically predicted plasma metabolites mediate the causal relationship between gut microbiota and osteosarcoma.
- Transketolase promotes osteosarcoma progression through the YY1-PAK4 axis.
- Characterization of the gut microbiota and fecal metabolome in the osteosarcoma mouse model.
- Cisplatin and doxorubicin chemotherapy alters gut microbiota in a murine osteosarcoma model.
- KNTC1 knockdown inhibits the proliferation and migration of osteosarcoma cells by MCM2.
- PRG4 represses the genesis and metastasis of osteosarcoma by inhibiting PDL1 expression.
- Natural Chlorogenic Acid Planted Nanohybrids with Steerable Hyperthermia for Osteosarcoma Suppression and Bone Regeneration.
- Osteosarcoma transcriptome data exploration reveals STC2 as a novel risk indicator in disease progression.
- 2-Hydroxy-3-methylanthraquinone inhibits homologous recombination repair in osteosarcoma through the MYC-CHK1-RAD51 axis.
- Transcriptomics and metabolomics reveal changes in the regulatory mechanisms of osteosarcoma under different culture methods in vitro.
- Necdin, one of the important pathway proteins in the regulation of osteosarcoma progression by microRNA-200c.
- A bone implant with NIR-responsiveness for eliminating osteosarcoma cells and promoting osteogenic differentiation of BMSCs.
- Exosomes loaded with programmed death ligand-1 promote tumor growth by immunosuppression in osteosarcoma.
- VEGF-C/VEGFR-3/iNOS Signaling in Osteosarcoma MG63 Cells Mediates Stimulatory Effects on Human Umbilical Vein Endothelial Cell Proliferation.
Earlier papers (2016–2020)3
- Long noncoding RNA LEF1-AS1 binds with HNRNPL to boost the proliferation, migration, and invasion in osteosarcoma by enhancing the mRNA stability of LEF1.
- miR-134 inhibits osteosarcoma cell invasion and metastasis through targeting MMP1 and MMP3 in vitro and in vivo.
- MicroRNA-134 inhibits osteosarcoma angiogenesis and proliferation by targeting the VEGFA/VEGFR1 pathway.
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 6 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Taiyuan for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07477587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led6
- SYK identified by bioinformatics analysis promotes the proliferation of multiple myeloma.
- RPL29 as a radiotherapy-sensitive prognostic biomarker in multiple myeloma.
- Development of a whole spinal MRI-based tumor burden scoring method in participants with multiple myeloma: a pilot study of prognostic significance.
- The quantitative parameters based on marrow metabolism derived from synthetic MRI: A pilot study of prognostic value in participants with newly diagnosed multiple myeloma.
- MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma.
- High expression of HOXC6 predicts a poor prognosis and induces proliferation and inflammation in multiple myeloma cells.
Chinese-language papers (not in the count)15
- [COX6C Promotes the Proliferation of Multiple Myeloma Cells by Increasing Intracellular ATP Levels].
- [Prognostic Value of Prothrombin Time and Activated Partial Thromboplastin Time in Newly Diagnosed Patients with Multiple Myeloma].
- [Mechanism and Clinical Significance of NAMPT in Multiple Myeloma].
- [Expression and Clinical Significance of NAMPT in Bone Marrow of Patients with Multiple Myeloma].
- [Research Progress on Mechanism of Bortezomib Resistance in Multiple Myeloma].
- [Risk Factors of Multiple Myeloma Complicated with Venous Thromboembolism].
- [Expression of NAMPT in Patients with Multiple Myeloma and Its Correlation with Clinical Manifestation].
- [Clinical Characteristics and Survival Analysis of Patients with Plasma Cell Leukemia].
- [The Value of Serum HMGB1 and sRAGE in the Diagnosis, Efficacy Monitoring and Prognosis of Newly Diagnosed Multiple Myeloma].
- [Evaluation of the Efficacy and Safety of Chemotherapy in Elderly Patients with Multiple Myeloma under Different Frailty Scores].
- [Clinical Characteristics and Prognosis of Multiple Myeloma Patients with Myelofibrosis].
- [Early Diagnosis of One Multiple Myeloma Patient with Cold Agglutinin Syndrome as the Initial Presentation].
- [Clinical Characteristics and Survival Analysis of Patients with IgD Multiple Myeloma].
- [Clinical Characteristic, Prognosis and Treatment Outcome of Elderly Multiple Myeloma Patients with Impaired Renal Function].
- [Clinical Analysis of 46 Cases of Multiple Myeloma with Extramedullary Disease].
All its trials on ClinicalTrials.gov, any status4
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
- A Pilot Bioequivalence Study of Pomalidomide
- A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Taiyuan for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
More papers found outside PubMed (not counted)1
Blood disorders
Haemophilia A
血友病 ALed 6 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 2.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Taiyuan for haemophilia A160 hospitals in China for haemophilia A
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingAn Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
- Phase
- Phase 1/Phase 2
- Started
- 2024-05
- Registry
- NCT07644832
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Hefei, Jinan, Lanzhou, Taiyuan, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led6
- Targeted genome engineering based on CRISPR/Cas9 system to enhance FVIII expression in vitro.
- Diagnostic Value of the HEAD-US-C Scale for the Knees of Severe Hemophilia A Patients.
- The Correlation Between the HEAD-US-C Score and HJHS in Hemophilic Arthropathy of the Knee.
- Molecular pathogenesis of a novel Met394Thr variant causing hemophilia B.
- Generation of iPSC line from urine cells of hemophilia A with F8 (p. R814X) mutation.
- Generation of an mESC model with a human hemophilia B nonsense mutation via CRISPR/Cas9 technology.
Chinese-language papers (not in the count)3
Earlier papers (2016–2020)2
- Spectrum of Molecular Defects in 216 Chinese Families With Hemophilia A: Identification of Noninversion Mutation Hot Spots and 42 Novel Mutations.
- Musculoskeletal ultrasonography for arthropathy assessment in patients with hemophilia: A single-center cross-sectional study from Shanxi Province, China.
All its trials on ClinicalTrials.gov, any status8
- An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
- A Phase I of SS109 in Hemophilia A or and B With Inhibitors
- Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
- An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
- Evaluate Efficacy and Safety of Recombinant Factor VIII (rFVIII)Treatment of Severe or Moderately Severe Hemophilia A
Blood disorders
Fanconi anaemia
范可尼贫血Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Taiyuan for Fanconi anaemia40 hospitals in China for Fanconi anaemia
No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
IgG4-related disease
IgG4相关性疾病Led 4 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 1.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Taiyuan for IgG4-related disease46 hospitals in China for IgG4-related disease
No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led4
- Clinical Performance of Immunonephelometric Assay and Chemiluminescent Immunoassay for Detection of IgG Subclasses in Chinese.
- Clinical Characteristics and CD4+ T Cell Subsets in IgG4-Related Disease.
- Response to "IgG4-Related Midline Destructive Disease" by Akiyama M.
- Immunoglobulin G4-Related Disease Involving the Nasal Septum and Trachea.
More papers found outside PubMed (not counted)1
Other diseases
Takayasu arteritis
大动脉炎Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Taiyuan for Takayasu arteritis108 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Taiyuan for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Taiyuan for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Fabry disease
法布雷病Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Taiyuan for Fabry disease85 hospitals in China for Fabry disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07187440
Age 7 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Behçet disease
白塞病Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Taiyuan for Behçet disease149 hospitals in China for Behçet disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- Phase
- Phase 3
- Started
- 2023-11
- Registry
- NCT06145893
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led1
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status1
Other diseases
IgA nephropathy
IgA 肾病Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Taiyuan for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Enteric-coated Mycophenolate Sodium plus hydroxychloroquine therApy versus hydroxychloroquine for the Remission of Proteinuria in IgA Nephropathy (EMSAR-IgAN trial): study protocol for a randomised trial.
- Management and Clinical Outcomes of Membranous Nephropathy, IgA Nephropathy, and Minimal Change Disease Two Years Post-Kidney Biopsy.
- Causal relationship between Helicobacter pylori infection and IgA nephropathy: a bidirectional two-sample mendelian randomization study.
- Risk factors for recurrent IgA nephropathy after renal transplantation: A meta-analysis.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status4
Other diseases
Osteogenesis imperfecta
成骨不全症Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Taiyuan for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta
No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Taiyuan for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis
No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)4
- Th17/Treg cell level and clinical characteristics of peripheral blood of patients with Sjogren's syndrome complicated with primary biliary cirrhosis.
- [Advances in the study of abnormal expression of genes related to primary biliary cholangitis].
- Primary myelofibrosis but not autoimmune myelofibrosis accompanied by Sjögren's syndrome and primary biliary cirrhosis in a patient with trisomy 8 mosaic: a case report and literature review.
- [Changes in peripheral blood 25 - hydroxyvitamin D3, Th17 cells, and CD4+ regulatory T cells and their clinical significance in patients with primary biliary cirrhosis].
Getting in touch
Name card to show staff or a driver
山西医科大学第二医院
Second Hospital of Shanxi Medical University
太原
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
West Hospital of the Second Hospital of Shanxi Medical University; Second hospital of Shanxi Medical University; Shanxi Medical University Second Clinical Medical College; Shanxi Red Cross Hospital